Immuno-Innovation is Mayer Brown’s blog reporting at the intersection of Immunotherapy and Intellectual Property law, providing legal analysis, updates on case law, legislative and regulatory developments, as well as trend-spotting and best practices. Our goal is to deliver to the pharmaceutical and biotech industry timely insights into where the science of immunotherapy is headed—and where patents and other IP might follow. Immuno-Innovation’s editors and contributors are members of Mayer Brown’s Intellectual Property practice and Life Sciences industry group; with decades of combined experience representing clients in the biopharmaceutical sector, our attorneys are uniquely qualified to contribute to the ongoing and important conversations about the critical intellectual property components of these life-savings therapies.